-
Trileptal May Cause Toxic Epidermal Necrolysis and Stevens Johnson Syndrome
Trileptal-induced TEN, SJS, and Hypersensitivity Reactions Reported to FDA In April 2005 the FDA and Novartis Pharmaceuticals Corp. issued a MedWatch safety alert about the risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis…
-
The Safety of Prescription Drugs During Pregnancy
FDA Uses Five Pregnancy Risk Categories At Present The FDA uses five risk categories to rank the safety of prescription drugs during pregnancy. In recent years, the FDA pregnancy risk categories have gone from…
-
Health Canada Put Adderall Back on the Market Based on “Inconclusive Evidence”
Safety of Adderall Cannot be Adequately Evaluated Says Expert Committee Chairman In the October 11, 2005 edition of the Canadian Medical Association Journal ("CMAJ"), an article by Wayne Kondro reveals that Health Canada reintroduced…
-
“Buyer Beware”, Especially If That New Drug Prescribed To You Was Just Approved By The FDA
FDA Approval Does Not Mean A New Drug Won’t Have Any Serious Side Effects In early October 2005, Jonathan D. Rockoff, of The Baltimore Sun, wrote a good article about an important issue for…
-
Controversy Over Safety of Heart Failure Drug Natrecor Continues
Doubting Its Safety, Dr. Eric Topol and Others Want Natrecor Recalled In the October 6, 2005 issue of The New England Journal of Medicine ("NEJM") appears a letter to the editor by Jonathan Sackner-Bernstein,…
-
Toprol: AstraZeneca and FDA Warn of Medication Errors Due to Similarly Named Drugs
"Dear Doctor" Letter About Reports of Patients Receiving Topamax and Tegretol Rather Than Toprol In late September 2005 the FDA and AstraZeneca warned of medication errors and pharmacy mistakes involving three brand-name medications: Toprol,…
